Ionis Pharmaceuticals Inc

NASDAQ:IONS  
44.24
-0.04 (-0.09%)
4:00:00 PM EDT: $44.23 -0.01 (-0.02%)
Products, Regulatory

Ionis Says Presents Positive Results From Phase 3 Neuro-Ttransform Study At International Symposium On Amyloidosis

Published: 09/07/2022 06:38 GMT
Ionis Pharmaceuticals Inc (IONS) - Ionis Presents Positive Results From Phase 3 Neuro-ttransform Study at International Symposium on Amyloidosis.
Eplontersen Demonstrated a Favorable Safety and Tolerability Profile.
Co and Astrazeneca's Eplontersen Demonstrated Statistically Significant and Clinically Meaningful Change From Baseline for Endpoints.
Will Seek Regulatory Approval for Eplontersen for Attrv-pn and Plan to File a New Drug Application With U.S. FDA This Year.